Ignacio J Amat-Santos
Latest contributions
TAVI in women
22 May 2025 – From EuroPCR 2025
Focus on gender-specific considerations in TAVI with this session. Topics include timely management and referral disparities in women with severe aortic stenosis, early outcomes from the LANDMARK trial with latest-generation valves, insights from NAVULTRA comparing valve types, prosthesis-patient mismatch data, and gender differences in right ventricular...
The Landmark RCT - One-year results
21 May 2025 – From EuroPCR 2025
This session presents a detailed analysis of a landmark randomized controlled trial evaluating the Myval transcatheter aortic valve implantation (TAVI) system among other contemporary transcatheter valves. The discussion centers on one-year clinical outcomes, with a particular focus on women, patients with small aortic annuli, and those...
Myval Octapro THV - Optimise patient outcomes with novel design, data and daily clinical practice
21 May 2025 – From EuroPCR 2025
This session presents the latest updates on the novel Myval Octapro transcatheter heart valve (THV), based on one year of real-world clinical experience. Experts share practical tips and clinical cases that highlight how this innovative device can improve TAVI patient outcomes. The session also addresses imaging and...
How to manage coronary artery disease in TAVI candidates?
20 May 2025 – From EuroPCR 2025
Understand the comprehensive management of coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI). This session reviews evidence-based evaluation, decision-making, and treatment strategies for significant coronary lesions, including severe left main and multivessel disease, illustrated through detailed case studies.
LANDMARK RCT - Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial
15 May 2024 – From EuroPCR 2024
This session provides an overview of the early outcomes of the LANDMARK trial, a randomized non-inferiority trial comparing TAVI devices. It examines baseline characteristics, the significance of intermediate sizes according to MSCT recommendations, real-world representative cases from the LANDMARK RCT, insights from quantitative aortography and echocardiography...
